Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.10.4369

In vitro Study of the Antagonistic Effect of Low-dose Liquiritigenin on Gemcitabine-induced Capillary Leak Syndrome in Pancreatic Adenocarcinoma via Inhibiting ROS-Mediated Signalling Pathways  

Wu, Wei (Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University)
Xia, Qing (Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University)
Luo, Rui-Jie (Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University)
Lin, Zi-Qi (Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University)
Xue, Ping (Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.10, 2015 , pp. 4369-4376 More about this Journal
Abstract
Background: To investigate in-vitro antagonistic effect of low-dose liquiritigenin on gemcitabine-induced capillary leak syndrome (CLS) in pancreatic adenocarcinoma via inhibiting reactive oxygen species (ROS)-mediated signalling pathways. Materials and Methods: Human pancreatic adenocarcinoma Panc-1 cells and human umbilical vein endothelial cells (HUVECs) were pre-treated using low-dose liquiritigenin for 24 h, then added into gemcitabine and incubated for 48 h. Cell viability, apoptosis rate and ROS levels of Panc-1 cells and HUVECs were respectively detected through methylthiazolyldiphenyl-tetrazoliumbromide (MTT) and flow cytometry. For HUVECs, transendothelial electrical resistance (TEER) and transcellular and paracellular leak were measured using transwell assays, then poly (ADP-ribose) polymerase 1 (PARP-1) and metal matrix proteinase-9 (MMP9) activity were assayed via kits, mRNA expressions of p53 and Rac-1 were determined through quantitative polymerase chain reaction (qPCR); The expressions of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and PARP-1 were measured via western blotting. Results: Low-dose liquiritigenin exerted no effect on gemcitabine-induced changes of cell viability, apoptosis rate and ROS levels in Panc-1 cells, but for HUVECs, liquiritigenin ($3{\mu}M$) could remarkably elevate gemcitabine-induced decrease of cell viability, transepithelial electrical resistance (TEER), pro-MMP9 level and expression of ICAM-1 and VCAM-1 (p<0.01). Meanwhile, it could also significantly decrease gemcitabine-induced increase of transcellular and paracellular leak, ROS level, PARP-1 activity, Act-MMP9 level, mRNA expressions of p53 and Rac-1, expression of PARP-1 and apoptosis rate (p<0.01). Conclusions: Low-dose liquiritigenin exerts an antagonistic effect on gemcitabine-induced leak across HUVECs via inhibiting ROS-mediated signalling pathways, but without affecting gemcitabine-induced Panc-1 cell apoptosis. Therefore, low-dose liquiritigenin might be beneficial to prevent the occurrence of gemcitabine-induced CLS in pancreatic adenocarcinoma.
Keywords
liquiritigenin; gemcitabine; capillary leak syndrome; pancreatic adenocarcinoma; reactive oxygen;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Axelsson J, Rippe A, Sverrisson K, et al (2013). Scavengers of reactive oxygen species, paracalcitol, RhoA, and Rac-1 inhibitors and tacrolimus inhibit angiotensin II-induced actions on glomerular permeability. Am J Physiol Renal Physiol, 5, 237-43.
2 Armstrong SM, Khajoee V, Wang C, et al (2012). Co-regulation of transcellular and paracellular leak across microvascular endothelium by dynamin and Rac. Am J Pathol, 180, 1308-23.   DOI
3 Biswas S, Nik S, Corrie PG (2004). Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease. Clin Oncol (R Coll Radiol), 16, 577-9.   DOI
4 Chen SH, Li DL, Yang F, et al (2014). Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation. Biochimie, 103, 71-9.   DOI
5 Choi EM, Suh KS, Lee YS (2014). Liquiritigenin restores osteoblast damage through regulating oxidative stress and mitochondrial dysfunction. Phytother Res, 28, 880-6.   DOI
6 Cheng ZX, Wang DW, Liu T, et al (2014). Effects of the HIF-1${\alpha}$ and NF-${\kappa}B$ loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells. Oncol Rep, 31, 1891-8.   DOI
7 Casadei Gardini A, Aquilina M, Oboldi D, et al (2013). Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer, 13, 542.   DOI
8 Dasanu CA (2008). Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf, 7, 703-16.   DOI
9 Dahan L, Ressiot E, Cournede A, et al (2007). Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer. Gastroenterol Clin Biol, 31, 1143-5.   DOI
10 De Pas T, Curigliano G, Franceschelli L, et al (2001). Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol, 12, 1651-2.   DOI
11 Gaur R, Yadav KS, Verma RK, et al (2014). In vivo anti-diabetic activity of derivatives of isoliquiritigenin and liquiritigenin. Phytomedicine, 21, 415-22.   DOI
12 Ju HQ, Gocho T, Aguilar M, et al (2014). Mechanisms of overcoming intrinsic resistance to gemcitabine in pancreatic ductal adenocarcinoma through the redox modulation. Mol Cancer Ther, [Epub ahead of print].
13 Liu DL, Bu HQ, Jin HM, et al (2014). Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway. Mol Med Rep, 10, 3027-34.   DOI
14 Matsuda A (1997). Nucleoside kinases and new types of antitumor nucleosides. Gan To Kagaku Ryoho, 24, 1594-9.
15 Liu Z, Li D, Zheng X, et al (2013). Selective induction of apoptosis: promising therapy in pancreatic cancer. Curr Pharm Des, 9, 2259-68.
16 Lau PC, Zheng SF, Ng WT, et al (2012). Inoperable pancreatic adenocarcinoma rendered complete remission by highintensity focused ultrasound concurrent with gemcitabinecapecitabine chemotherapy: case report and topic review. J Dig Dis, 13, 60-4.   DOI
17 Montero J, Dutta C, van Bodegom D, et al (2013). p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ, 20, 1465-74.   DOI
18 Peng F, Du Q, Peng C, et al (2015). A review: the pharmacology of isoliquiritigenin. Phytother Res, [Epub ahead of print].
19 Park SM, Ki SH, Han NR, et al (2015). Tacrine, an oral acetylcholinesterase inhibitor, induced hepatic oxidative damage, which was blocked by liquiritigenin through GSK3-beta inhibition. Biol Pharm Bull, 38, 184-92.   DOI
20 Pulkkanen K, Kataja V, Johansson R (2003). Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemother, 15, 287-9.   DOI
21 Pan X, Kong LD, Zhang Y, et al (2000). In-vitro inhibition of rat monoamine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. Acta Pharmacol Sin, 21, 949-53.
22 Suzuki S, Okada M, Shibuya K, et al (2015). JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget, 6, 458-70.   DOI
23 Stein DM, Scalea TM, (2012). Capillary leak syndrome in trauma: what is it and what are the consequences? Adv Surg, 46, 237-53.   DOI
24 Srinivasan B, Kolli AR, Esch MB, et al (2015). TEER measurement techniques for in vitro barrier model systems. J Lab Autom, 20, 107-26.   DOI
25 Singh M, Kaur M, Silakari O (2014). Flavones: an important scaffold for medicinal chemistry. Eur J Med Chem, 84, 206-39.   DOI
26 Suh KS, Rhee SY, Kim YS, et al (2014). Protective effect of liquiritigenin against methylglyoxal cytotoxicity in osteoblastic MC3T3-E1 cells. Food Funct, 5, 1432-40.   DOI
27 Taylor SC, Posch A (2014). The design of a quantitative western blot experiment. Biomed Res Int, 2014, 361590.
28 Vacas E, Bajo AM, Schally AV, et al (2013). Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma. Mol Cell Endocrinol, 365, 212-22.   DOI
29 Wang R, Cheng L, Xia J, et al (2014). Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1${\alpha}$ in pancreatic cancer cells. Curr Cancer Drug Targets, 14, 407-17.   DOI
30 Wu X, Deng G, Li M, et al (2013). Wnt/${\beta}$-Catenin signaling reduces Bacillus Calmette-Guerin-induced macrophage necrosis through a ROS-mediated PARP/AIF-dependent pathway. BMC Immunol, 16, 16.
31 Wong BS, Yoong SL, Jagusiak A, et al (2013). Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev, 65, 1964-2015.   DOI
32 Xie X, Zhang HD, Chen YZ, et al (2012). Chemical constituents and activities of total flavonoids from Yushen Tang. Chinese Materia Medica, 37, 3585-90.
33 Zhan YH, Huang XF, Hu XB, et al (2013). Growth inhibition and apoptosis induction of human umbilical vein endothelial cells by apogossypolone. Asian Pac J Cancer Prev, 14, 1791-5.   DOI
34 Yang EJ, Park GH, Song KS (2013). Neuroprotective effects of liquiritigenin isolated from licorice roots on glutamate-induced apoptosis in hippocampal neuronal cells. Neurotoxicology, 39, 114-23.   DOI